Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Demyelinating Autoimmune Diseases, CNS Clear all
Completed Phase 3 Interventional Results available

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

NCT03093324
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
ALKS 8700, Dimethyl Fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
57
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Jul 23, 2026, 5:06 AM EDT
Completed No phase listed Observational

Evaluation of Natalizumab for thE Relief of MS Associated FatiGue

NCT00464074
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
30
States / cities
Phoenix, Arizona • Fresno, California • Atlanta, Georgia + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Jul 23, 2026, 5:06 AM EDT
Completed Not applicable Interventional Results available

Adherence in Pediatric Multiple Sclerosis

NCT02234713
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Motivational Interview, Video Attention Control
Behavioral · Other
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
10 Years to 18 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
11
States / cities
Birmingham, Alabama • Loma Linda, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Jul 23, 2026, 5:06 AM EDT
Recruiting Not applicable Interventional

High-Intensity, Dynamic-stability Gait Training in People With Multiple Sclerosis

NCT05735691
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
High-Intensity Treadmill Training, Treadmill Training with Perturbations, Standard Treadmill Training
Procedure
Lead sponsor
Marquette University
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Indianapolis, Indiana • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Jul 23, 2026, 5:06 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Deciphering Preserved Autonomic Function After Multiple Sclerosis

NCT07012135
View directory record Official record
Conditions
Multiple Sclerosis, Control Subjects, Autonomic Dysreflexia
Interventions
Tests of sympathetic inhibition, Tests of sympathetic activation, Testing of autonomic dysreflexia
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 23, 2026, 5:06 AM EDT
Completed Not applicable Interventional Results available

Light Therapy as Treatment for Fatigue in Multiple Sclerosis

NCT03060759
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Light Therapy box
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Jul 23, 2026, 5:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)

NCT02258217
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Acthar
Drug
Lead sponsor
OhioHealth
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Jul 23, 2026, 5:06 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

NCT06408259
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ozanimod, Fingolimod, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
10 Years to 17 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
12
States / cities
Loma Linda, California • Sacramento, California • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 23, 2026, 5:06 AM EDT
Completed Not applicable Interventional

Ukulele Playing to Improve Cognition in People with Multiple Sclerosis: a Feasibility Study

NCT05792176
View directory record Official record
Conditions
Multiple Sclerosis, Pathologic Processes, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Demyelinating Diseases, Autoimmune Diseases, Immune System Diseases
Interventions
Music Training Intervention, Music Listening
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Jul 23, 2026, 5:06 AM EDT
Enrolling by invitation No phase listed Observational

A Long Term Follow-Up Study for Subjects Who Have Received Q-Cells

NCT06163508
View directory record Official record
Conditions
Transverse Myelitis
Interventions
Q-Cells®
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 23, 2026, 5:06 AM EDT
Completed Not applicable Interventional

Computerized Cognitive Training in MS

NCT03737825
View directory record Official record
Conditions
Multiple Sclerosis, Cognitive Decline
Interventions
Computerized gaming rehabilitation Program 1, Computerized gaming rehabilitation Program 2
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 23, 2026, 5:06 AM EDT
Completed No phase listed Observational

Ocrelizumab Effects on the Metabolome in MS

NCT03873389
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Jul 23, 2026, 5:06 AM EDT
Completed Phase 2 Interventional

Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis

NCT00772525
View directory record Official record
Conditions
Multiple Sclerosis, Optic Nerve, Neuritis
Interventions
Nerispirdine, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Jul 23, 2026, 5:06 AM EDT
Recruiting Not applicable Interventional

Investigating the Effects of Wearable Robotic Exoskeleton for Improving Mobility and Cognition in Persons With MS

NCT04855825
View directory record Official record
Conditions
Multiple Sclerosis, Gait Disorders, Neurologic, Motility Disorder, Cognitive Impairment
Interventions
Robotic Exoskeleton Rehabilitation, Conventional Gait Therapy
Device · Other
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Jul 23, 2026, 5:06 AM EDT
Completed No phase listed Observational

A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis

NCT01541618
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
MSDX Complex-1 Biomarker test
Other
Lead sponsor
MSDx, Inc.
Industry
Eligibility
45 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Jul 23, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

Neuroprotection With Riluzole Patients With Early Multiple Sclerosis

NCT00501943
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Avonex (Interferon beta 1a), Riluzole, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Jul 23, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

NCT00879658
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
BAF312, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
16
States / cities
Cullman, Alabama • San Francisco, California • Centennial, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Jul 23, 2026, 5:06 AM EDT
Completed Phase 1 Interventional

A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis

NCT02601885
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ABT-555, Placebo
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
8
States / cities
Orlando, Florida • Lenexa, Kansas • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Jul 23, 2026, 5:06 AM EDT
Terminated Phase 3 Interventional Results available

BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis

NCT02430532
View directory record Official record
Conditions
Multiple Sclerosis, Secondary Progressive
Interventions
dimethyl fumarate, Placebo
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 58 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Long Beach, California • San Francisco, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Jul 23, 2026, 5:06 AM EDT
Completed Phase 1 Interventional Results available

Safety of Polyphenon E in Multiple Sclerosis Pilot Study

NCT00836719
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Polyphenon E
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Jul 23, 2026, 5:06 AM EDT
Completed Not applicable Interventional

Effect of Guided Imagery on Well-being in Patients With Multiple Sclerosis

NCT03177655
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Guided Imagery, Journaling
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Jul 23, 2026, 5:06 AM EDT
Recruiting Not applicable Interventional

A Palliative Care Model Impact on Knowledge and Attitudes

NCT06860932
View directory record Official record
Conditions
Multiple Sclerosis, MS
Interventions
Palliative care video comprises the conversation and advance directives., Palliative care written material
Behavioral
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 23, 2026, 5:06 AM EDT
Not listed Phase 4 Interventional

Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects

NCT03424733
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Plegridy, Prednisone, Tylenol Pill
Drug
Lead sponsor
Holy Name Medical Center, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Teaneck, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 14, 2019 · Synced Jul 23, 2026, 5:06 AM EDT
Completed No phase listed Observational

Utilization of the Ketogenic Diet in Patient With Relapsing Remitting MS

NCT03718247
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Modified Atkins diet
Other
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Jul 23, 2026, 5:06 AM EDT